Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Hewlett Packard Enterprise Co — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.34 (market cap $12.58B), while Hewlett Packard Enterprise Co trades at $73.12 (market cap $94.25B). The key difference: Hewlett Packard Enterprise Co is far larger — about 7.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Hewlett Packard Enterprise Co for 33 Days on average.
| HALO | HPE | |
|---|---|---|
Market Cap | $12.58B | $94.25B |
Volume | 2,179,278 | 16,060,854 |
Sector | Health | Technology |
52-Week High | $115.22 | $72.12 |
52-Week Low | $61.63 | $20.01 |
Typical Hold Time | 1 Days | 33 Days |
Enterprise Value | $14.49B | $108.28B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HPE trades at $71.75, near its all-time high, with strong momentum driven by AI infrastructure demand. The stock has gained over 160% year-over-year and recently received a bullish upgrade from Daiwa. Recent earnings beats and a $1.2 billion AI server order from Vultr highlight operational strength. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026.
Outlook remains positive with AI-driven growth catalysts, though valuation multiples appear elevated. Key risks include execution on Juniper integration and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting limited near-term upside from current levels despite strong business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
